Allovectin-7

Allovectin-7

A gene-based product containing HLA-B7, an antigen responsible for strong immune responses such as transplant organ rejection; Allovectin-7 injection into cancer might theoretically trigger the body's immune system to recognise the cancer as foreign and destroy it.

It was granted orphan drug status for the management of melanoma and is in Phase-3 trials for managing advanced melanoma.
References in periodicals archive ?
These vaccines include Allovectin-7 and OncoVEX, for the treatment of Melanoma, BiovaxId (Idiotype vaccine therapy) for follicular non-Hodgkin lymphoma, and GV1001 for advanced pancreatic cancer.
A Phase 3 pivotal trial comparing Allovectin-7 alone vs.
Vical) today announced the start of phase III of their clinical trial of Allovectin-7 -a gene therapy treatment drug for progressive melanoma patients.
MINNEAPOLIS -- Interim results from a phase II trial indicate that Allovectin-7 is an active, well-tolerated treatment for advanced metastatic melanoma patients, Dr.
The new patent covers a range of applications of the company's core DNA delivery technology, including cationic lipid-formulated, gene-based immunotherapeutics such as Vical's clinical-stage Allovectin-7 treatment for melanoma, cationic lipid-formulated DNA vaccines such as Vical's developmental anthrax vaccine, and similar pharmaceutical products under development by others.
Ten years ago, Allovectin-7 was in a similar position, but it failed to meet its efficacy endpoint in phase III.
29 January 2010 - US biopharmaceutical products maker Vical Incorporated (NASDAQ: VICL) said yesterday it has completed enrollment of the planned 375 subjects in its Phase III trial of Allovectin-7 in patients with metastatic melanoma.
Tokyo, Japan, May 30, 2006 - (JCN) - AnGes MG announced on May 30 that it has signed a collaboration agreement with US bio venture company Vical for Allovectin-7, Vical's proprietary immunotherapeutic for malignant melanoma.
Vical's two lead product candidates, Allovectin-7 and Leuvectin, both involve direct injection of genetic material into tumors or surrounding tissue using lipids to facilitate delivery.
28 December 2009 - US-based biopharmaceutical products developer Vical Incorporated (NASDAQ: VICL) said today that an independent Safety Monitoring Board (SMB) for its Phase III AIMM trial of Allovectin-7 in patients with metastatic melanoma has completed the trial's third scheduled safety analysis and recommended that the study continue per the protocol.
Collategene by AnGes MG, Cardium Therapeutics' Generx, and Vical Incorporation's Allovectin-7 are in development for a wide range of cancer indications, and are expected to compete in the oncology therapeutics market as the market acceptance of gene therapy improves over time.